Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/12/2026, 7:53:37 PM
Content snapshot
{ "session_id": "sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222549-20260402_20260412-195337", "round_number": 3, "agent_persona": "persona-domain_expert", "agent_backend": "minimax/MiniMax-M2.7", "action": "support", "content": "\n\n# Domain Expert Evaluation: SEA-AD Translational Potential\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Ranked by Clinical Feasibility\n\n**#1: Microglial State Characterization with Therapeutic Stratification**\nSEA-AD's single-nucleus resolution positions it to define microglial subpopulations (DAM, ARM, M2-like) with unprecedented precision. This directly informs patient selection for immunomodulatory trials (anti-Aβ antibodies, TREM2 agonists).\n\n**#2: Lipid Metabolism / DHA Metabolite Signature**\nIf SEA-AD donors show distinct oxysterol or resolvin signatures, this could identify responders for omega-3 intervention—a low-risk, already-approved intervention with equivocal trial data that might succeed in properly selected subgroups.\n\n**#3: Astrocyte Reactivity Subtyping**\nGiven lecanemab's emerging success andARIA-E concerns, understanding astrocyte states that predict amyloid-related edema could directly improve safety stratification.\n\n*Note: The wildfire-AHR hypothesis (#1 as presented) ranks lowest on translational potential despite mechanistic appeal, for reasons the Skeptic correctly identified.*\n\n---\n\n## 2. Clinical Evidence, Safety, and Population Fit\n\n### Hypothesis: TREM2-Pathway Microglial States\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Clinical Evidence** | TREM2 R47H/R62H variants show ~2-4× increased AD risk; TREM2 agonism (AL002, GSK3907124A) in Phase I/II. Human PET-MRI studies show microglial activation correlates with cognitive decline independent of amyloid burden. |\n| **Safety Considerations** | Agonistic antibodies carry theoretical risk of over-activating microglia (pseudo-inflammatory state), but early trials show acceptable tolerability. Biomarker monitoring (NfL", "tokens_used": "437" }